Rhabdomyosarcoma: Updates on classification and the necessity of molecular testing beyond immunohistochemistry

Hum Pathol. 2024 May:147:72-81. doi: 10.1016/j.humpath.2023.12.004. Epub 2023 Dec 21.

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents under the age of 20. The current World Health Organization (WHO) classification for soft tissue and bone tumors recognizes 4 distinct subtypes of RMS based on clinicopathological and molecular genetic features: embryonal, alveolar, spindle cell/sclerosing and pleomorphic subtypes. However, with the increased use of molecular techniques, the classification of rhabdomyosarcoma has been evolving rapidly. New subtypes such as osseus RMS harboring TFCP2/NCOA2 fusions or RMS arising in inflammatory rhabdomyoblastic tumor have been emerging within the last decade, adding to the complexity of diagnosing skeletal muscle tumors. This review article provides an overview of classically recognized distinctive subtypes as well as new, evolving subtypes and discusses important morphologic, immunophenotypic and molecular genetic features of each subtype including recommendations for a diagnostic approach of malignant skeletal muscle neoplasms.

Keywords: Alveolar; Embryonal; FOXO1; Rhabdomyosarcoma; Sarcoma; Spindle cell/sclerosing.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor* / analysis
  • Biomarkers, Tumor* / genetics
  • Child
  • Genetic Predisposition to Disease
  • Humans
  • Immunohistochemistry*
  • Molecular Diagnostic Techniques
  • Phenotype
  • Predictive Value of Tests
  • Rhabdomyosarcoma* / classification
  • Rhabdomyosarcoma* / diagnosis
  • Rhabdomyosarcoma* / genetics
  • Rhabdomyosarcoma* / pathology
  • Soft Tissue Neoplasms / classification
  • Soft Tissue Neoplasms / diagnosis
  • Soft Tissue Neoplasms / genetics
  • Soft Tissue Neoplasms / pathology

Substances

  • Biomarkers, Tumor